Challenges and opportunities in the generics and biosimilars industry.
Current challenges.
The generics industry is facing high cost pressure - the average tablet price in Germany is just six cents. At the same time, a technological backlog is hampering innovations such as 3D printing, which offer enormous potential. In addition, rising quality and safety requirements are significantly increasing the regulatory burden. Read more about the generics markets
Opportunities through technological innovations.
Advances in digitalization and artificial intelligence are enabling more efficient processes in production and distribution. Platforms such as Amazon Pharmacy show how digital ecosystems can revolutionize the industry by opening up new ways of creating value. Find out more about the platform economy
Four scenarios for the future of the generics and biosimilars industry.
1. new rules in the old home country.
In this scenario, disruptive market dynamics dominate, while traditional value creation models remain intact. Regulatory intervention characterizes the market and manufacturers continue to rely on proven technologies.
2. the platform economy takes over.
Digital platforms such as Amazon Pharmacy are setting the rules of the game here. They are revolutionizing distribution channels and creating completely new value creation models that are replacing conventional approaches.
3. the industry is migrating.
Production sites are relocating to more cost-effective regions, such as Africa. This evolutionary scenario combines traditional value creation models with a relocation of the production base.
4. reorientation through digital health.
This scenario is characterized by an evolutionary market dynamic that is shaped by innovative value creation models such as patient-specific therapies and mobile production solutions.
Future drivers and recommendations for action.
Technology as a key driver.
Technologies such as 3D printing enable individualized and cost-efficient drug production. Artificial intelligence offers optimized risk analyses and strategic decision-making. More about technological innovations here
Recommendations for manufacturers.
Investments in digitalization and automation are essential, as are strategic partnerships with platform providers and the development of flexible supply chains. These measures ensure competitiveness and open up new market potential. Find out more about supply chain adjustments
Expert assessments of the future.
Dr. Ingmar Hoerr (CureVac founder):
"The individualization of medicine is made possible by mobile RNA printers. Generics and biosimilar manufacturers should keep a close eye on this development, as it could be disruptive in the long term."
Thomas Hillek (KPMG):
"The generics and biosimilars industry must become more agile and digital. The platform economy and e-commerce will permanently change the competitive landscape."
Conclusion.
The generics and biosimilars industry is facing a paradigm shift. By focusing on innovation, digitalization and strategic partnerships, companies can master the challenges of the future and ensure long-term success.
